Literature DB >> 22447751

Responding to requests of families for unproven interventions in neurodevelopmental disorders: hyperbaric oxygen "treatment" and stem cell "therapy" in cerebral palsy.

Emily Bell1, Tessa Wallace, Isabelle Chouinard, Michael Shevell, Eric Racine.   

Abstract

Faced with the limitations of currently available mainstream medical treatments and interventions, parents of children with neurodevelopmental disorders often seek information about unproven interventions. These interventions frequently have undetermined efficacy and uncertain safety profiles. In this article, we present a general background and case vignettes that highlight the use of hyperbaric oxygen chambers and stem cells in cerebral palsy, the leading cause of pediatric physical disability. We then review the current evidence about these interventions as exemplars of unproven therapies. Building on the background and cases, we explore and review two important questions related to unproven interventions: (1) How should clinicians respond to requests for innovative and alternative interventions? (2) What should clinicians keep in mind when such requests come from online sources?
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22447751     DOI: 10.1002/ddrr.134

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  3 in total

1.  Chinese newspaper coverage of (unproven) stem cell therapies and their providers.

Authors:  Ubaka Ogbogu; Li Du; Christen Rachul; Lisa Bélanger; Timothy Caulfield
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

2.  Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.

Authors:  Amy Zarzeczny; Marianne Clark
Journal:  BMC Med Ethics       Date:  2014-10-14       Impact factor: 2.652

Review 3.  New Ethical Issues in Cerebral Palsy.

Authors:  Bernard Dan
Journal:  Front Neurol       Date:  2021-03-19       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.